Circular Genomics
About
Circular Genomics is a biotechnology company based in Albuquerque, New Mexico, founded in 2021. The company specializes in precision psychiatry by utilizing circular RNA biomarkers to enhance the diagnosis and treatment of psychiatric and neurological disorders. Their innovative approach aims to reduce the trial-and-error methods currently used in treatment selection. One of their key offerings is MindLight™, a blood-based test that predicts patient responses to SSRI antidepressants for Major Depressive Disorder (MDD). This test provides a biomarker-driven method to streamline treatment, addressing the lengthy trial period typically associated with SSRIs. Circular Genomics is also developing additional circular RNA biomarker tests to improve diagnostic accuracy and therapeutic monitoring in psychiatry. The company has raised over $12.8 million in funding, with a recent $8.3 million round in January 2024 to advance its circular RNA assay. Circular Genomics is committed to serving healthcare providers and patients, particularly those affected by MDD, and aims to improve mental healthcare through its research and innovative diagnostic tools.